INGN

Inogen Inc. (INGN) | Rumor.io

Inogen

INGN

Attention (50-day avg)0%

Attention rank (50-day avg)#3,987

Bullish sentiment (50-day avg)88%

Price to earnings ratio-6.33

Market capitalization144.4M

Earnings per share-0.91

Dividend yield (TTM)—

Revenue (annual)348.7M

Net income (annual)-22.7M

Social

What share of all stock conversation is about INGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% +0

Jul 24

Inogen, Inc. ($INGN) has a low enterprise value of $64M compared to its revenue of $351.5M, with a price-to-sales ratio of 0.18x.
The company has a debt-free balance sheet with over 60% of its market cap in cash, or $111.5M, and is growing with 2026 guidance at 6% growth.
Inogen's valuation is significantly lower than its peers, with a price-to-sales ratio of 0.18x compared to 1.5x to 5.8x for other companies in the industry.

Generated by AI

Sentiment

Of the messages about INGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	80% -11.3	93.37% +20.29
Bearish	0%	0%	20% +11.3	6.63% -20.29

Bullish· Feb 24

Inogen, Inc. (INGN) has announced a $30M share repurchase program, indicating confidence in its stock and future prospects.
The company has beaten expectations, with a strong Q1 sales forecast of $366M-$373M, and a positive full-year Adjusted EBITDA for the first time since 2021.
INGN's guidance for 2026 includes 6% revenue growth and a commitment to driving positive Adjusted EBITDA improvement, suggesting a steady and optimistic outlook for the company.

Bearish· Aug 5

Inogen's stock price has dropped significantly, with a 31.26% decline, due to supply chain constraints and analyst downgrades.
The company's stock has been downgraded by KeyBanc Capital Markets to Sector Weight from Overweight, citing supply chain constraints that will impact the second half of FY21.
Inogen's stock price has been overvalued and the current pullback is an overreaction, with the 57-58 area expected to provide support but sellers showing no signs of giving up.

Generated by AI

Topics

Of the messages about INGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	88.89%	81.25%
Earnings	—	—	11.11%	9.38%
Macro	—	—	0%	3.13%
Technical Analysis	—	—	0%	5.63%
Analysts	—	—	0%	0.63%
Controversies	—	—	0%	0%

Earnings· Nov 5

Inogen reported Q3 earnings of 31c EPS, beating estimates by 5c, and revenue of $91.76M, missing estimates by $0.23M.
Inogen's Q3 sales decreased 4% and earnings declined 58% compared to the same period in 2018.
Inogen reaffirmed its FY19 revenue guidance and provided a revised FY20 revenue guidance above consensus estimates.

Analysts· Jun 8

Needham & Company LLC raised the price target for Inogen Inc (INGN) to $108.00 from $96.00.
Needham & Company LLC maintains a strong-buy rating for Inogen Inc (INGN) with a price target of $108.00.
Needham & Company LLC lowered its target for Inogen Inc (INGN), citing fundamentals that support a strong-buy rating.

Generated by AI

Community

Of the messages about INGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	25%	34.65%
Newcomers	0%	0%	75%	65.35%

Regulars· Feb 24

Inogen, Inc. ($INGN) is set to provide a strategy update on February 27, 2023, following a recent large block trade of 20,000 shares at $15.635.
The company has announced its fourth quarter and full year 2022 financial results, with Needham maintaining a Buy rating and lowering the price target to $36 from $26.
Inogen's recent earnings call transcript is available, providing insight into the company's performance, and a form 10-K has been filed with the SEC, detailing the company's financial situation.

Newcomers· Jul 22

Many newcomers are focusing on Inogen's inability to turn a profit, which they see as a major concern for the company's future.
Some newcomers are questioning the company's ability to meet increasing demand, citing a decrease in profitability.
Others are expressing skepticism about the company's spending on research and development, citing increasing SG&A spending as a negative factor.

Generated by AI

News

Here's Why You Should Retain Inogen Stock in Your Portfolio for Now

INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.

1mo agoYahoo Finance

Inogen (INGN) Cuts Guidance Even As Profitability Climbs

On August 6, Inogen (NASDAQ:INGN) reported second-quarter results that captured the company’s split personality right now. International sales keep compounding, new products are finding buyers, and profitability is improving. But the US business is still losing ground to a structural shift in how patients get oxygen therapy, and that weakness was enough to push full-year […]

1mo agofinance.yahoo.com

Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists

INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.

1mo agoYahoo Finance

Should Investors Buy Inogen as Low Valuation Meets Execution Risk?

Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.

1mo agoYahoo Finance

Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut

1mo agosg.finance.yahoo.com

Inogen (INGN) Has a New Rating from B. Riley Securities

Detailed price information for Inogen Inc (INGN-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about INGN also mention

#	Name	Attention
1	ABMD - Abiomed, Inc.	——
2	NVRO - Nevro Corp.	——
3	Paylocity Holding CorporationPCTY	0%0
4	ResMed Inc.RMD	0%0
5	Varonis Systems, Inc.VRNS	0%new
6	Ligand Pharmaceuticals IncorporatedLGND	0%0
7	Invesco Top QQQ ETFQBIG	0%0
8	Vanguard Short-Term Inflation-Protected Securities Index FundVTIP	0.01%0
9	BOK Financial CorporationBOKF	0%0
10	Apogee Therapeutics, Inc. - Common StockAPGE	0%0

Inogen Inc.

Healthcare
Medical Devices

Inogen Inc. is a medical technology company focused on respiratory care for people living with chronic respiratory conditions. The company develops, manufactures, and markets portable oxygen concentrators for homecare use, helping patients receive supplemental long-term oxygen therapy in a more mobile form than traditional oxygen systems. Its product portfolio also includes stationary home oxygen concentrators, batteries, accessories, rental offerings, and airway-clearance solutions. Inogen serves patients through direct-to-consumer, business-to-business, and international channels, working with home medical equipment providers, prescribers, and distributors to broaden access to respiratory therapy products. Headquartered in Beverly, Massachusetts, Inogen plays a specialized role in the respiratory health market by addressing everyday oxygen therapy needs across home, travel, and other ambulatory settings.

Website

Location

500 Cummings Center

Beverly, MA, 01915

United States

Social

What share of all stock conversation is about INGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% +0

Jul 24

Inogen, Inc. ($INGN) has a low enterprise value of $64M compared to its revenue of $351.5M, with a price-to-sales ratio of 0.18x.
The company has a debt-free balance sheet with over 60% of its market cap in cash, or $111.5M, and is growing with 2026 guidance at 6% growth.
Inogen's valuation is significantly lower than its peers, with a price-to-sales ratio of 0.18x compared to 1.5x to 5.8x for other companies in the industry.

Generated by AI

Sentiment

Of the messages about INGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	80% -11.3	93.37% +20.29
Bearish	0%	0%	20% +11.3	6.63% -20.29

Bullish· Feb 24

Inogen, Inc. (INGN) has announced a $30M share repurchase program, indicating confidence in its stock and future prospects.
The company has beaten expectations, with a strong Q1 sales forecast of $366M-$373M, and a positive full-year Adjusted EBITDA for the first time since 2021.
INGN's guidance for 2026 includes 6% revenue growth and a commitment to driving positive Adjusted EBITDA improvement, suggesting a steady and optimistic outlook for the company.

Bearish· Aug 5

Inogen's stock price has dropped significantly, with a 31.26% decline, due to supply chain constraints and analyst downgrades.
The company's stock has been downgraded by KeyBanc Capital Markets to Sector Weight from Overweight, citing supply chain constraints that will impact the second half of FY21.
Inogen's stock price has been overvalued and the current pullback is an overreaction, with the 57-58 area expected to provide support but sellers showing no signs of giving up.

Generated by AI

Topics

Of the messages about INGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	88.89%	81.25%
Earnings	—	—	11.11%	9.38%
Macro	—	—	0%	3.13%
Technical Analysis	—	—	0%	5.63%
Analysts	—	—	0%	0.63%
Controversies	—	—	0%	0%

Earnings· Nov 5

Inogen reported Q3 earnings of 31c EPS, beating estimates by 5c, and revenue of $91.76M, missing estimates by $0.23M.
Inogen's Q3 sales decreased 4% and earnings declined 58% compared to the same period in 2018.
Inogen reaffirmed its FY19 revenue guidance and provided a revised FY20 revenue guidance above consensus estimates.

Analysts· Jun 8

Needham & Company LLC raised the price target for Inogen Inc (INGN) to $108.00 from $96.00.
Needham & Company LLC maintains a strong-buy rating for Inogen Inc (INGN) with a price target of $108.00.
Needham & Company LLC lowered its target for Inogen Inc (INGN), citing fundamentals that support a strong-buy rating.

Generated by AI

Community

Of the messages about INGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	25%	34.65%
Newcomers	0%	0%	75%	65.35%

Regulars· Feb 24

Inogen, Inc. ($INGN) is set to provide a strategy update on February 27, 2023, following a recent large block trade of 20,000 shares at $15.635.
The company has announced its fourth quarter and full year 2022 financial results, with Needham maintaining a Buy rating and lowering the price target to $36 from $26.
Inogen's recent earnings call transcript is available, providing insight into the company's performance, and a form 10-K has been filed with the SEC, detailing the company's financial situation.

Newcomers· Jul 22

Many newcomers are focusing on Inogen's inability to turn a profit, which they see as a major concern for the company's future.
Some newcomers are questioning the company's ability to meet increasing demand, citing a decrease in profitability.
Others are expressing skepticism about the company's spending on research and development, citing increasing SG&A spending as a negative factor.

Generated by AI

Inogen

Social

Jul 24

Bullish· Feb 24

Bearish· Aug 5

Earnings· Nov 5

Analysts· Jun 8

Regulars· Feb 24

Newcomers· Jul 22

Here's Why You Should Retain Inogen Stock in Your Portfolio for Now

Inogen (INGN) Cuts Guidance Even As Profitability Climbs

Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists

Should Investors Buy Inogen as Low Valuation Meets Execution Risk?

Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut

Inogen (INGN) Has a New Rating from B. Riley Securities

Also Discussed

Inogen Inc.

Company Information

Location

Here's Why You Should Retain Inogen Stock in Your Portfolio for Now

Inogen (INGN) Cuts Guidance Even As Profitability Climbs

Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists

Should Investors Buy Inogen as Low Valuation Meets Execution Risk?

Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut

Inogen (INGN) Has a New Rating from B. Riley Securities

Also Discussed

Social

Jul 24

Bullish· Feb 24

Bearish· Aug 5

Earnings· Nov 5

Analysts· Jun 8

Regulars· Feb 24

Newcomers· Jul 22